A pan-cancer analysis of HAVCR1 with a focus on diagnostic, prognostic and immunological roles in human cancers

Guangyao Li; Muhammad Javed; Rubab Rasool; Mostafa A Abdel-Maksoud; Ayman S Mubarak; Christian R Studenik; J Narayanan; Sampson Agyapong Atuahene; Mohammed Aufy; Kun Cao

A pan-cancer analysis of HAVCR1 with a focus on diagnostic, prognostic and immunological roles in human cancers

Am J Transl Res. 2023 Mar 15;15(3):1590-1606. eCollection 2023.

Authors

Affiliations

¹ Department of Gastrointestinal Surgery, The Second People's Hospital of Wuhu Wuhu, Anhui, The People's Republic of China.
² Primary and Secondary Health Care Department Lahore, Pakistan.
³ Health Bridge Hospital, Defense Housing Authority Lahore, Pakistan.
⁴ Botany and Microbiology Department, College of Science, King Saud University Riyadh 11451, Saudi Arabia.
⁵ Department of Pharmaceutical Sciences, Division of Pharmacology and Toxicology, University of Vienna Vienna, Austria.
⁶ SRM College of Pharmacy SRMIST Chennai, India.
⁷ Department of Curriculum and Pedagogy, College of Teacher Education, Zhejiang Normal University Jinhua 321004, China.
⁸ Department of General Surgery, The First People's Hospital of Hefei Hefei, Anhui, The People's Republic of China.

PMID: 37056808
PMCID: PMC10086885

Abstract

Objectives: Cancer is one of the most prominent causes of death world wide. Identification of novel cancer biomarkers woud help with cancer diagnosis and possible treatment.

Methods: In this study, we comprehensively studied the diagnostic, prognostic, and therapeutic values of the hepatitis A virus cellular receptor 1 (HAVCR1) gene across multiple cancers from a pan-cancer point of view via a detailed in silico approach.

Results: HAVCR1 expression was up-regulated in a variety of malignancies. The up-regulated HAVCR1 was closely related to the poor prognosis in patients with esophageal carcinoma (ESCA), lung adenocarcinoma (LUAD), and stomach adenocarcinoma (STAD). Moreover, DAVID analysis showed that HAVCR1, along with different other associated genes, was involved in numerous cancer-associated signaling pathways across ESCA, STAD, and LUAD. Furthermore, in these cancers, HAVCR1 was also found closely associated with some other parameters such as promoter methylation, tumor purity, level of CD8+ T immune cells, genomic alterations, and chemotherapeutic drugs.

Conclusion: HAVCR1 was overexpressed in multiple tumors. However, the up-regulated HAVCR1 is a valuable diagnostic and prognostic biomarker as well as a therapeutic target in only ESCA, STAD, and LUAD patients.

Keywords: HAVCR1; biomarker; pan-cancer; therapeutic.